Plasma metanephrines: A novel and cost-effective test for pheochromocytoma

Brazilian Journal of Medical and Biological Research

Volumn 33, Issue 10, 2000, Pages 1157-1169

  Eisenhofer, G ^a,f   Walther, M ^b   Keiser, H R ^c   Lenders, J W M ^d   Friberg, P ^e   Pacak, K ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Adrenal gland; Catecholamines; Hypertension; Metanephrines; Pheochromocytoma; Sympathetic nervous system

Indexed keywords

CATECHOLAMINE; METADRENALIN; TUMOR MARKER;

ADRENAL TUMOR; BLOOD; COST BENEFIT ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; PHEOCHROMOCYTOMA; REVIEW; SENSITIVITY AND SPECIFICITY;

ADRENAL GLAND NEOPLASMS; CATECHOLAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COST-BENEFIT ANALYSIS; HUMANS; HYPERTENSION; METANEPHRINE; PHEOCHROMOCYTOMA; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0034297063     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2000001000005     Document Type: Article

References (37)

1. Goldstein DS (1995). Stress, Catecholamines, and Cardiovascular Disease. Oxford University Press, New York.
2. Sinclair D, Shenkin A & Lorimer AR (1991). Normal catecholamine production in a patient with a paroxysmally secreting phaeochromocytoma. Annals of Clinical Biochemistry, 28: 417-419.
3. Stewart MF, Reed P, Weinkove C, Moriarty KJ & Ralston AJ (1993). Biochemical diagnosis of phaeochromocytoma: two instructive case reports. Journal of Clinical Pathology, 46: 280-282.
4. Bravo EL (1994). Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocrine Reviews, 15: 356-368.
5. Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppenborg PW, Thien T & Eisenhofer G (1995). Plasma metanephrines in the diagnosis of pheochromocytoma. Annals of Internal Medicine, 123: 101-109.
6. Shawar L & Svec F (1996). Pheochromocytoma with elevated metanephrines as the only biochemical finding. Journal of the Louisiana State Medical Society, 148: 535-538.
7. Eisenhofer G, Lenders JWM, Linehan WM, Walther MM, Goldstein DS & Keiser HR (1999). Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. New England Journal of Medicine, 340: 1872-1879.
8. Eisenhofer G, Goldstein DS & Kopin IJ (1989). Plasma dihydroxyphenylglycol for estimation of noradrenaline neuronal reuptake in the sympathetic nervous system in vivo. Clinical Science, 76: 171-182.
9. Eisenhofer G (1994). Plasma normetanephrine for examination of extraneuronal uptake and metabolism of noradrenaline in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 349: 259-269.
10. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS & Esler MD (1996). Cardiac sympathetic nerve function in congestive heart failure. Circulation, 93: 1667-1676.
11. Graefe KH & Henseling M (1983). Neuronal and extraneuronal uptake ard metabolism of catecholamines. General Pharmacology, 14: 27-33.
12. Eisenhofer G, Goldstein DS, Ropchak TG, Nguyen HQ, Keiser HR & Kopin IJ (1988). Source and physiological significance of plasna 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. Journal of the Autonomic Nervous System, 24: 1-14.
13. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR & Kopin IJ (1988). Plasma dihydroxyphenylglycol anc the intraneuronal disposition of norepinephrine in humans. Journal of Clinical Investigation, 81: 213-220.
14. Eisenhofer G, Pecorella W, Pacak K, Hooper D, Kopn IJ & Goldstein DS (1994). The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. Journal of the Autonomic Nervous System, 50: 93-107.
15. Eisenhofer G, Smolich JJ & Esler MD (1992). Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anaesthetized dog. Naunyn-Schmiedeberg's Archives of Pharmacology, 345: 160-171.
16. Brown M (1984). Simultaneous assay of noradrenaline and its deaminated metabolite, dihydroxyphenylglycol, in plasma: a simplified approach to the exclusion of pheochromocytoma in patients with borderline elevation of plasma noradrenaline concentration. European Journal of Clinical Investigation, 14: 67-72.
17. Duncan MW, Compton P, Lazarus L & Smythe GA (1988). Measurement of norepinephrine and 3,4-dihydroxyphenylglycol in urine and plasma for the diagnosis of pheochromocytoma. New England Journal of Medicine, 319: 136-142.
18. Atuk NO, Hanks JB, Weltman J, Bogdonoff DL, Boyd DG & Vance ML (1994). Circulating dihydroxyphenylglycol and norepinephrine concentrations during sympathetic nervous system activation in patients with pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 79: 1609-1614.
19. Nakada T, Sasagawa I, Kubota Y, Suzuki H, Ishigooka M & Watanabe M (1996). Dihydroxyphenylglycol in pheochromocytoma: its diagnostic use for norepinephrine dominant tumor. Journal of Urology, 155: 14-18
20. Eisenhofer G, Aneman A, Hooper D, Rundqvist B & Friberg P (1996). Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humans. Journal of Neurochemistry, 66: 1565-1573.
21. Mardh G, Luehr CA & Vallee BL (1985). Human class I alcohol dehydrogenases catalyze the oxidation of glycols in the metabolism of norepinephrine. Proceedings of the National Academy of Sciences, USA, 82: 4979-4982.
22. Mardh G, Dingley AL, Auld DS & Vallee BL (1986). Human class II (pi) alcohol dehydrogenase has a redox-specific function in norepinephrine metabolism. Proceedings of the National Academy of Sciences, USA, 83: 8908-8912.
23. Peastor RT & Lai LC (1993). Biochemical detection of phaechromocytoma: Should we still be measuring urinary HMMA? Journal of Clinical Pathology, 46: 734-737
24. Neumann HP, Berger DP, Sigmund G, Blum U. Schmidt D, Parmer RJ, Volk B & Kirste G (1993). Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. New England Journal of Medicine, 329: 1531-1538.
25. Tormey WP & FitzGerald RJ (1995). Phaeochromocytoma - a laboratory experience. Irish Journal of Medical Science, 164: 142-145.
26. Mornex R & Peyrin L (1996). The biological diagnosis of pheochromocytoma. Bulletin et Memoires de l'Academie Royale de Medecine de Belgique, 151: 269-277.
27. Peaston RT, Lennard TW & Lai LC (1996). Overnight excretion of urinary catecholamines and metabolites in the detection of pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 81: 1378-1384.
28. Eisenhofer G, Rundqvist B, Aneman A, Friberg P, Dakak N, Kopin IJ, Jacobs MC & Lenders JW (1995). Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. Journal of Clinical Endocrinology and Metabolism, 80: 3009-3017.
29. Eisenhofer G, Friberg P, Pacak K, Goldstein DS, Murphy DL, Tsigos C, Quyyumi AA, Brunner HG & Lenders JW (1995). Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism? Clinical Science, 88: 533-542.
30. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, Ellingson T, Duddempudi S, Eijsbouts A & Lenders JW (1998). Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. Journal of Clinical Endocrinology and Metabolism, 83: 2175-2185.
31. Roth JA (1992). Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. Review of Physiology, Biochemistry and Pharmacology, 120: 1-29.
32. Eisenhofer G & Finberg JP (1994). Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats. Journal of Pharmacology and Experimental Therapeutics, 268: 1242-1251.
33. Lenders JWM, Eisenhofer G, Abeling NG, Berger W, Murphy DL, Konings CH, Wagemakers LM, Kopin IJ, Karoum F, van Gennip AH & Brunner HG (1996). Specific genetic deficiencies of the A and B isozymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. Journal of Clinical Investigation, 97: 1010-1019.
34. Box JC, Braithwaite MD, Duncan T & Lucas G (1997). Pheochromocytoma, chronic renal insufficiency, and hemodialysis: a combination leading to a diagnostic and therapeutic dilemma. American Surgeon, 63: 314-316.
35. Peynn L, Cottet-Emard JM, Pagliari R, Cottet-Emard RM, Badet C & Mornex R (1994). Plasma methoxyamines assay: a practical advance for the diagnosis of pheochromocytoma. Pathologie Biologie, 42: 847-854.
36. Karsdorp N, Elderson A, Wittebol-Post D, Hene RJ, Vos J, Feldberg MA, van Gils AP, Jansen-Schillhorn van Veen JM, Vroom TM, Hoppener JW & Lips CJM (1994). Von Hippel-Lindau disease: new strategies in early detection and treatment. American Journal of Medicine, 97: 158-168.
37. Aprill BS, Drake AJ, Lasseter DH & Shakir KM (1994). Silent adrenal nodules in von Hippel-Lindau disease suggest pheochromocytoma. Annals of Internal Medicine, 120: 485-487.